Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group
The study,
The study evaluated the efficacy and safety of tyrosine kinase inhibitors (TKIs) in patients with advanced bone sarcomas, including osteosarcoma, chondrosarcoma, and Ewing sarcoma. It showed that TKIs had limited survival outcomes but an acceptable safety profile in a real‑world setting, consistent with phase II trial results.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Revisiting CDKN2A dysregulation in Ewing sarcoma
- Emerging therapies in Ewing sarcoma
- Genome‑wide association study meta‑analysis identifies susceptibility loci informing Ewing sarcoma etiology and potential mechanisms of risk
- Biochemists discover new strategy to combat pediatric bone cancer
- Integrated Immunotherapy Target Atlas for Ewing Sarcoma